|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
|
EP1736478B1
(en)
|
2000-05-26 |
2015-07-22 |
IDENIX Pharmaceuticals, Inc. |
Methods and compositions for treating flaviviruses and pestiviruses
|
|
LT1576138T
(lt)
|
2002-11-15 |
2017-06-26 |
Idenix Pharmaceuticals Llc |
2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija
|
|
RS53347B
(sr)
|
2008-12-09 |
2014-10-31 |
Gilead Sciences, Inc. |
Modulatori toll-sličnih receptora
|
|
HUE030465T2
(hu)
*
|
2009-05-13 |
2017-05-29 |
|
Antivirális vegyületek
|
|
ES2524356T3
(es)
|
2010-07-22 |
2014-12-05 |
Gilead Sciences, Inc. |
Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
|
|
US20130273005A1
(en)
|
2010-12-20 |
2013-10-17 |
Gilead Sciences, Inc. |
Methods for treating hcv
|
|
US9243025B2
(en)
|
2011-03-31 |
2016-01-26 |
Idenix Pharmaceuticals, Llc |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
AR088441A1
(es)
|
2011-09-12 |
2014-06-11 |
Idenix Pharmaceuticals Inc |
Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
|
|
EP2709613B2
(en)
|
2011-09-16 |
2020-08-12 |
Gilead Pharmasset LLC |
Methods for treating hcv
|
|
US8507460B2
(en)
|
2011-10-14 |
2013-08-13 |
Idenix Pharmaceuticals, Inc. |
Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
|
DE202012012955U1
(de)
|
2011-10-21 |
2014-07-14 |
Abbvie Inc. |
Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
|
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
|
EP2583677A3
(en)
|
2011-10-21 |
2013-07-03 |
Abbvie Inc. |
Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
|
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
|
US9326973B2
(en)
|
2012-01-13 |
2016-05-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
|
JP6165848B2
(ja)
|
2012-05-22 |
2017-07-19 |
イデニク ファーマシューティカルズ エルエルシー |
肝疾患のためのｄ−アミノ酸化合物
|
|
WO2013177188A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
|
US9296778B2
(en)
|
2012-05-22 |
2016-03-29 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphate prodrugs for HCV infection
|
|
MX2014014323A
(es)
|
2012-05-25 |
2015-02-12 |
Janssen R & D Ireland |
Nucleosidos de espirooxetano de uracilo.
|
|
US8759544B2
(en)
*
|
2012-08-17 |
2014-06-24 |
Gilead Sciences, Inc. |
Synthesis of an antiviral compound
|
|
US8927741B2
(en)
*
|
2012-08-17 |
2015-01-06 |
Gilead Sciences, Inc. |
Synthesis of an antiviral compound
|
|
US8841340B2
(en)
*
|
2012-08-17 |
2014-09-23 |
Gilead Sciences, Inc. |
Solid forms of an antiviral compound
|
|
WO2014052638A1
(en)
|
2012-09-27 |
2014-04-03 |
Idenix Pharmaceuticals, Inc. |
Esters and malonates of sate prodrugs
|
|
EP2906579B1
(en)
|
2012-10-08 |
2018-04-18 |
Idenix Pharmaceuticals LLC. |
2'-chloro nucleoside analogs for hcv infection
|
|
US10723754B2
(en)
|
2012-10-22 |
2020-07-28 |
Idenix Pharmaceuticals Llc |
2′,4′-bridged nucleosides for HCV infection
|
|
EP2935304A1
(en)
|
2012-12-19 |
2015-10-28 |
IDENIX Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
|
EP2950786B1
(en)
|
2013-01-31 |
2019-11-27 |
Gilead Pharmasset LLC |
Combination formulation of two antiviral compounds
|
|
WO2014137930A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
Thiophosphate nucleosides for the treatment of hcv
|
|
WO2014137926A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
3'-deoxy nucleosides for the treatment of hcv
|
|
WO2014160484A1
(en)
|
2013-03-13 |
2014-10-02 |
Idenix Pharmaceuticals, Inc. |
Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
|
|
EP2981542B1
(en)
|
2013-04-01 |
2021-09-15 |
Idenix Pharmaceuticals LLC |
2',4'-fluoro nucleosides for the treatment of hcv
|
|
US10005779B2
(en)
|
2013-06-05 |
2018-06-26 |
Idenix Pharmaceuticals Llc |
1′,4′-thio nucleosides for the treatment of HCV
|
|
US20150023913A1
(en)
|
2013-07-02 |
2015-01-22 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
|
US9717712B2
(en)
|
2013-07-02 |
2017-08-01 |
Bristol-Myers Squibb Company |
Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
|
|
US9775831B2
(en)
|
2013-07-17 |
2017-10-03 |
Bristol-Myers Squibb Company |
Combinations comprising biphenyl derivatives for use in the treatment of HCV
|
|
WO2015017713A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
|
PT3038601T
(pt)
|
2013-08-27 |
2020-06-30 |
Gilead Pharmasset Llc |
Formulação combinada de dois compostos antivirais
|
|
UA119050C2
(uk)
|
2013-11-11 |
2019-04-25 |
Ґілеад Саєнсиз, Інк. |
ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
|
|
US10202411B2
(en)
|
2014-04-16 |
2019-02-12 |
Idenix Pharmaceuticals Llc |
3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
|
|
CN104140417B
(zh)
*
|
2014-06-11 |
2016-04-06 |
苏州景泓生物技术有限公司 |
合成gs5885用的中间体的先期化合物的合成方法
|
|
JP6522732B2
(ja)
|
2014-07-11 |
2019-05-29 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｉｖを治療するためのトール様受容体の調節因子
|
|
TWI678369B
(zh)
|
2014-07-28 |
2019-12-01 |
美商基利科學股份有限公司 |
用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
|
|
TWI673283B
(zh)
|
2014-08-21 |
2019-10-01 |
美商基利科學股份有限公司 |
２’－氯胺基嘧啶酮及嘧啶二酮核苷類
|
|
SG11201701520TA
(en)
*
|
2014-09-16 |
2017-04-27 |
Gilead Sciences Inc |
Solid forms of a toll-like receptor modulator
|
|
KR102306860B1
(ko)
*
|
2014-09-16 |
2021-09-30 |
길리애드 사이언시즈, 인코포레이티드 |
톨-유사 수용체 조정제를 제조하는 방법
|
|
TWI687432B
(zh)
|
2014-10-29 |
2020-03-11 |
美商基利科學股份有限公司 |
絲狀病毒科病毒感染之治療
|
|
JP7381190B2
(ja)
|
2014-12-26 |
2023-11-15 |
エモリー・ユニバーシテイ |
Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
|
|
CA3182565A1
(en)
|
2015-03-06 |
2016-09-15 |
Atea Pharmaceuticals, Inc. |
.beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
|
|
WO2017023631A1
(en)
|
2015-08-06 |
2017-02-09 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
|
DK3785717T3
(da)
|
2015-09-16 |
2022-03-21 |
Gilead Sciences Inc |
Fremgangsmåder til behandling af coronaviridae-infektioner
|
|
CN105646626B
(zh)
*
|
2016-02-24 |
2018-04-24 |
贵州理工学院 |
一种高收率索氟布韦的合成方法
|
|
JP6551263B2
(ja)
|
2016-03-02 |
2019-07-31 |
株式会社デンソー |
ヘッドアップディスプレイ装置
|
|
CN105669358A
(zh)
*
|
2016-03-17 |
2016-06-15 |
中国药科大学 |
多取代芴衍生物的氟化方法
|
|
EA201892448A1
(ru)
|
2016-04-28 |
2019-06-28 |
Эмори Юниверсити |
Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
|
|
CN105968040B
(zh)
*
|
2016-06-29 |
2019-02-05 |
爱斯特（成都）生物制药股份有限公司 |
一种雷迪帕韦中间体的制备方法
|
|
CN106432197B
(zh)
*
|
2016-09-07 |
2019-12-10 |
上海众强药业有限公司 |
一种雷迪帕韦中间体单对甲苯磺酸盐、其晶型及其制备方法
|
|
IL288737B
(en)
|
2017-02-01 |
2022-09-01 |
Atea Pharmaceuticals Inc |
Hemisulfate nucleotide salt for treatment of hepatitis c virus
|
|
US10682368B2
(en)
|
2017-03-14 |
2020-06-16 |
Gilead Sciences, Inc. |
Methods of treating feline coronavirus infections
|
|
CA3059777C
(en)
*
|
2017-05-01 |
2023-02-21 |
Gilead Sciences, Inc. |
Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
|
|
WO2019014247A1
(en)
|
2017-07-11 |
2019-01-17 |
Gilead Sciences, Inc. |
COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
|
|
NZ762505A
(en)
|
2017-09-29 |
2026-03-27 |
Daiichi Sankyo Co Ltd |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
|
PT3706762T
(pt)
|
2017-12-07 |
2024-12-05 |
Univ Emory |
N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
|
|
SG11202104993SA
(en)
|
2018-11-14 |
2021-06-29 |
Daiichi Sankyo Co Ltd |
Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate
|
|
EP3670488A1
(en)
|
2018-12-18 |
2020-06-24 |
Basf Se |
Bi- and tricyclic ketones for use as aroma chemicals
|
|
WO2020196475A1
(ja)
|
2019-03-25 |
2020-10-01 |
第一三共株式会社 |
抗ｈｅｒ２抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
|
|
CN113631229B
(zh)
|
2019-03-25 |
2025-09-23 |
第一三共株式会社 |
抗体－吡咯并苯并二氮杂卓衍生物偶联物
|
|
CA3139180A1
(en)
|
2019-03-27 |
2020-10-01 |
Daiichi Sankyo Company, Limited |
Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
|
|
WO2020202142A2
(en)
|
2019-03-31 |
2020-10-08 |
Yeda Research And Development Co. Ltd. |
Anti-viral and anti-tumoral compounds
|
|
TWI810456B
(zh)
|
2019-05-22 |
2023-08-01 |
美商基利科學股份有限公司 |
Tlr7調節化合物及hiv疫苗之組合
|
|
JP2023512656A
(ja)
|
2020-01-27 |
2023-03-28 |
ギリアード サイエンシーズ， インコーポレイテッド |
ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
|
|
CN113214262B
(zh)
*
|
2020-02-05 |
2023-07-07 |
华创合成制药股份有限公司 |
一种含有胍基的化合物及其制备方法和用途
|
|
TWI883391B
(zh)
|
2020-02-18 |
2025-05-11 |
美商基利科學股份有限公司 |
抗病毒化合物
|
|
KR20250133471A
(ko)
|
2020-02-18 |
2025-09-05 |
길리애드 사이언시즈, 인코포레이티드 |
항바이러스 화합물
|
|
TWI775313B
(zh)
|
2020-02-18 |
2022-08-21 |
美商基利科學股份有限公司 |
抗病毒化合物
|
|
TWI791193B
(zh)
|
2020-02-18 |
2023-02-01 |
美商基利科學股份有限公司 |
抗病毒化合物
|
|
KR20220153619A
(ko)
|
2020-03-12 |
2022-11-18 |
길리애드 사이언시즈, 인코포레이티드 |
1'-시아노 뉴클레오사이드의 제조 방법
|
|
CA3172483A1
(en)
|
2020-04-06 |
2021-10-14 |
Scott Ellis |
Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
|
|
TW202203941A
(zh)
|
2020-05-29 |
2022-02-01 |
美商基利科學股份有限公司 |
瑞德西韋之治療方法
|
|
CN111620903A
(zh)
*
|
2020-06-17 |
2020-09-04 |
安徽贝克联合制药有限公司 |
C-核苷类似物以及用于合成瑞德西韦合成的含腈c-核苷类化合物的制备方法及其应用
|
|
PE20230618A1
(es)
|
2020-06-24 |
2023-04-14 |
Gilead Sciences Inc |
Analogos de nucleosido de 1'-ciano y usos de los mismos
|
|
EP4228656A4
(en)
|
2020-08-18 |
2024-09-04 |
Yeda Research and Development Co. Ltd |
ANTI-VIRAL AND ANTI-TUMOR COMPOUNDS
|
|
IL300453A
(en)
|
2020-08-27 |
2023-04-01 |
Gilead Sciences Inc |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
|
|
CA3216162A1
(en)
|
2021-04-16 |
2022-10-20 |
Gilead Sciences, Inc. |
Methods of preparing carbanucleosides using amides
|
|
US12497408B2
(en)
|
2021-05-21 |
2025-12-16 |
Gilead Sciences, Inc. |
Tetracyclic compounds and methods for the treatment of Zika virus infection
|
|
US12037340B2
(en)
|
2021-05-21 |
2024-07-16 |
Gilead Sciences, Inc. |
Pentacyclic derivatives as Zika virus inhibitors
|
|
IL308921A
(en)
|
2021-06-17 |
2024-01-01 |
Atea Pharmaceuticals Inc |
Combination anti-HCV therapy is beneficial
|
|
TW202317145A
(zh)
*
|
2021-06-17 |
2023-05-01 |
美商亞堤製藥公司 |
有利之抗hcv組合療法
|
|
AU2022328698B2
(en)
|
2021-08-18 |
2025-02-20 |
Gilead Sciences, Inc. |
Phospholipid compounds and methods of making and using the same
|
|
KR20240154647A
(ko)
|
2022-03-02 |
2024-10-25 |
길리애드 사이언시즈, 인코포레이티드 |
바이러스성 감염 치료를 위한 화합물 및 방법
|
|
US12357577B1
(en)
|
2024-02-02 |
2025-07-15 |
Gilead Sciences, Inc. |
Pharmaceutical formulations and uses thereof
|